FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/12/2024
Voltar para busca
Dado oficial do USPTO
BRIDGE CAR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
21/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
13/12/2022
Data de registro
18/06/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/06/2024
Última transação
18/06/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
AU
Examinador
BULLOFF, TOBY
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Biosceptre (Aust) Pty Ltd
Representantes
Timothy J. Kelly T.J. KELLY INTELLECTUAL PROPERTY LAW, P.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Biopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseasescancercardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseasescancercardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; veterinary preparationsnamely biopharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; veterinary preparationsnamely pharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; biological preparations for veterinary purposesnamely biopharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; biological preparations for veterinary purposesnamely pharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; cultures of microorganisms for medical and veterinary use; biological preparations for medical purposesnamely biopharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; biological preparations for medical purposesnamely pharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; drugs for medical purposesnamely biopharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; drugs for medical purposesnamely pharmaceutical preparations for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; diagnostic preparations for medical purposes; enzymes for medical purposes; biochemical medicines for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; vaccines; bioengineering pharmaceutical solutions for use in expanding cells for therapeutic use to patients with blood cancers and other diseases; biopharmaceuticalsnamely biopharmaceutical products for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; cells and biological preparationsbloodstem cellsadult blood cellsimmune cellsimmunomodulatory cellsumbilical cord cellsumbilical cord bloodplacental tissue intended for medical and clinical useincludingbloodstem cellsadult blood cellsimmune cellsimmunomodulatory cellsumbilical cord cellsumbilical cord bloodplacental tissue; bioengineered cells for use in immunotherapies; diagnostic substances and diagnostic preparations for medical purposes; gene and cell therapy and prophylaxis productstherapeutic pharmaceuticals for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; gene and cell therapy prophylaxis vector preparations for therapeutic purposes for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; pharmaceutical preparations and productsnamely pharmaceutical preparations and products for use in the treatment of autoimmune diseasescancertumorsblood-related diseasesinflammationcardiovascular diseases and disordersendocrine diseases and disordersgastrointestinal diseases and disordersinfectious diseasespsychiatric and psychological diseases and disordersneurological diseases and disordersrespiratory diseases and disorders; pharmaceutical preparations in the nature of cell solutions to enable cell expansion for therapeutic purposes; reagents for ex vivo cell processing in particular media suitable for the expansion of cells for therapeutic purposes; cell products for therapeutic purposesnamely stem and progenitor celladult cellimmune cellcell therapy and gene therapy products; cells for medical purposes
Classe 42
Analysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of diseaseinjuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientificmedical and clinical research consultation services and scientificmedical and clinical research and development servicesincluding in the field of hematologyimmunologycancer researchdevelopmental biology and life sciencesbiotechnologymedical technologycell culturetissue engineeringgenetic engineeringregenerative medicineimmunotherapy and immunomodulation; medical and scientific researchconducting pre-clinical and clinical trials for others; pharmaceuticalmedicalscientificbiotechnologybiopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development in the field of computational biologybioinformaticsgenomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations and substances for use in clinical trials; chemical analysis; industrial design; conducting technical project studies in the fields of medicinebiotechnologytherapeuticspharmaceuticalsbiopharmaceuticalsbiotherapeuticsradiologycardiologyoncologyepidemiologypulmonologyneurologyhematologyendocrinologyotolaryngologygastroenterologynephrologygynecologyobstetricsurologyorthopedicsophthalmologypathologypediatricssurgerymedical geneticsmedical genomicsdermatologyimmunologypreventive medicine; research and development of new products for others; material testing; biological research; scientific laboratory services; scientific research; bacteriological research
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/12/2024
FIMP
FINAL DISPOSITION PROCESSED
04/12/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
18/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/06/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
18/06/2024
GPNX
NOTIFICATION PROCESSED BY IB
16/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/04/2024
PUBO
PUBLISHED FOR OPPOSITION
02/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/03/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/02/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
28/02/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/02/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
28/02/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/02/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/02/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/02/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/02/2024
RFNT
REFUSAL PROCESSED BY IB
25/10/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/09/2023
RFRR
REFUSAL PROCESSED BY MPU
30/09/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/09/2023
CNRT
NON-FINAL ACTION WRITTEN
18/09/2023
DOCK
ASSIGNED TO EXAMINER
18/09/2023
MAFR
APPLICATION FILING RECEIPT MAILED
02/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/04/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/04/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BRIDGE CAR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.